Capillarisin
Based on 1 publication(s) in Google Scholar
Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties. Capillarisin can be used for the research of asthma-mediated complications and can be a potential neuroprotectant against bupivacaine-induced neurotoxicity.
For research use only. We do not sell to patients.
- Purity : 98.42%
- CAS No.: 56365-38-9
- Formula: C16H12O7
- Molecular Weight:316.26
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Capillarisin
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
1.1 μg/mL
Compound: Capillarisin
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by XTT assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by XTT assay
|
[PMID: 31784199] |
In Vitro
Capillarisin (0~40 μM; 24 hours; SH-SY5Y cells) does not produce any significant changes on the viability of SH-SY5Y cells[3].
.
Capillarisin (40 μM; 24 hours; SH-SY5Y cells) induces PI3K/PKB pathway inactivation, which inhibiting apoptosis in bupivacaine-challenged SH-SY5Y cells is overturned by LY294002 treatment and counteracts bupivacaine-induced injury via activating the PI3K/PKB pathway[3].
.
Capillarisin antagonizes bupivacaine-induced oxidative stress via activating the PI3K/PKB pathway in SH-SY5Y cells. Capillarisin inhibits bupivacaine-induced mitochondrial injury and endoplasmic reticulum stress via activating PI3K/PKB pathway[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SH-SY5Y cells
-
Concentration:0~40 μM
-
Incubation Time:24 hours
-
Result:Did not produce any significant changes on the viability of SH-SY5Y cells.
-
Cell Line:SH-SY5Y cells
-
Concentration:40 μM
-
Incubation Time:24 hours
-
Result:Induced PI3K/PKB pathway inactivation in SH-SY5Y cells.
-
Cell Line:SH-SY5Y cells
-
Concentration:40 μM
-
Incubation Time:24 hours
-
Result:Induced inhibition of apoptosis in bupivacaine-challenged SH-SY5Y cells was overturned by LY294002 treatment.
In Vivo
Capillarisin significantly reduces the plasma leading nitrite production. Capillarisin markedly suppresses the adenosine 5'-triphosphate (ATP) in plasma and substance P in CFA-induced paw tissue[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice[4]
-
Dosage:20 and 80 mg/kg
-
Administration:I.p.; 1 hour
-
Result:Pretreatment strongly inhibited NF-κB mediated genes (iNOS, COX-2).
Chemical Information
-
CAS No. 56365-38-9
-
Appearance Solid
-
Molecular Weight 316.26
-
Formula C16H12O7
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(OC2=CC=C(O)C=C2)OC3=CC(O)=C(OC)C(O)=C13
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 13 mg/mL (41.11 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Neurotoxicity Study
This protocol assesses in vitro neurotoxicity by combining neuronal viability, mitochondrial/metabolic activity, neurite outgrowth, and optional neuronal network function readouts. Calcein-AM or resazurin/PrestoBlue readouts estimate viable or metabolically active cells; βIII-tubulin immunofluorescence detects neuronal morphology and neurite networks; TMRE detects mitochondrial membrane potential; and MEA recordings detect functional changes in neuronal network activity.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Peng G, et al. Capillarisin exerts antiasthmatic activity in neonatal rats via modulating the matrix remodeling. Pak J Pharm Sci. 2020;33(4(Supplementary)):1907-1915. [Content Brief]
[3]. Zhao T, Wang Q. Capillarisin protects SH-SY5Y cells against bupivacaine-induced apoptosis via ROS-mediated PI3K/PKB pathway. Life Sci. 2020;259:118279. [Content Brief]
[4]. Khan S, et al. Anti-hyperalgesic and anti-allodynic activities of capillarisin via suppression of inflammatory signaling in animal model. J Ethnopharmacol. 2014;152(3):478-486. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1620 mL | 15.8098 mL | 31.6196 mL | 79.0489 mL |
| 5 mM | 0.6324 mL | 3.1620 mL | 6.3239 mL | 15.8098 mL | |
| 10 mM | 0.3162 mL | 1.5810 mL | 3.1620 mL | 7.9049 mL | |
| 15 mM | 0.2108 mL | 1.0540 mL | 2.1080 mL | 5.2699 mL | |
| 20 mM | 0.1581 mL | 0.7905 mL | 1.5810 mL | 3.9524 mL | |
| 25 mM | 0.1265 mL | 0.6324 mL | 1.2648 mL | 3.1620 mL | |
| 30 mM | 0.1054 mL | 0.5270 mL | 1.0540 mL | 2.6350 mL | |
| 40 mM | 0.0790 mL | 0.3952 mL | 0.7905 mL | 1.9762 mL |
Capillarisin Related Classifications
HY-121192 Related Classifications
Powered by Bioz